Cadiogen, Audentes Therapeutics deal

Audentes acquired fellow rare disease company Cardiogen for an undisclosed amount. Audentes gains AT003 (formerly CASQ2-CPVT), a preclinical adeno-associated virus (AAV) vector-based therapy that del...